10-Q: PURE Bioscience Reports Q1 2025 Results with Revenue Decline and Continued Losses

PURE Bioscience reported a decrease in net product sales and a net loss for the first quarter of fiscal year 2025, while also raising additional capital through convertible notes.

Summary

• PURE Bioscience reported a net product sales of $555,000 for the three months ended October 31, 2024, a decrease from $718,000 in the same period of 2023.
• The company's total revenue for the quarter was $556,000, down from $722,000 in the prior year.
• Cost of goods sold decreased to $231,000 from $280,000 year-over-year.
• The company experienced a net loss of $689,000 for the quarter, compared to a net loss of $735,000 in the same period last year.
• Operating expenses were $952,000, down from $1,153,000 year-over-year.
• The company's cash and cash equivalents decreased slightly to $346,000 from $349,000 at the end of the previous quarter.
• The company has a stockholders deficiency of $3,496,000 as of October 31, 2024.
• The company raised $500,000 through a convertible note agreement with related parties during the quarter.
• The company's independent auditor has expressed substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position with declining sales, continued losses, and a going concern warning. While there are some positive aspects like reduced operating expenses, the overall sentiment is negative due to the company's financial instability and reliance on further capital raises.

Positives

• The company's net loss decreased slightly year-over-year, from $735,000 to $689,000.
• Operating expenses decreased by $192,000 year-over-year, primarily due to decreased personnel costs and facilities expenses.
• The company secured $500,000 in financing through convertible notes with related parties.

Negatives

• Net product sales decreased by $163,000 year-over-year.
• The company's gross margin percentage decreased from 61% to 58%.
• The company continues to operate at a loss, with a net loss of $689,000 for the quarter.
• The company has a significant stockholders deficiency of $3,496,000.
• The company's independent auditor has expressed substantial doubt about the company's ability to continue as a going concern.

Risks

• The company has a history of recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• The company's future capital requirements depend on numerous factors, including market acceptance of its products and regulatory approvals.
• The company may need to raise additional capital through equity or debt financing, which could result in dilution or restrictive covenants.
• The company's operating results have fluctuated significantly in the past and are likely to continue to do so in the future.
• The company is dependent on a few key customers, with two customers accounting for 30% and 10% of net product sales for the quarter.
• The company is dependent on a few key vendors, with one vendor accounting for 33% of purchases for the quarter.

Future Outlook

The company's future capital requirements depend on numerous factors, including market acceptance of its products, regulatory approvals, and the costs of further developing its products and technologies. The company will need to continue to fund its operations with the proceeds of offerings of its equity and debt securities until it can generate positive cash flow from operations.

Management Comments

• Management believes that the period-to-period comparisons of our operating results are not a reliable indication of our future performance.
• Management states that the company is dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control.
• Management states that the company aims to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain.

Industry Context

The company operates in the antimicrobial solutions market, specifically targeting the food industry. The company's products are designed to address food safety risks, which is a growing concern in the industry. The company's strategy includes expanding its distribution network and partnering with third parties to market its products outside the U.S.

Comparison to Industry Standards

• PURE Bioscience's financial performance is weak compared to established companies in the antimicrobial and food safety sectors.
• Companies like Ecolab and Diversey, which are major players in the hygiene and sanitation market, have significantly higher revenue and profitability.
• PURE Bioscience's reliance on a few key customers and vendors is a risk not typically seen in larger, more diversified companies.
• The company's negative cash flow and going concern issues are not typical of established companies in the industry.
• The company's gross margin of 58% is lower than some competitors in the chemical manufacturing sector, which can achieve gross margins of 60-70%.

Related Party Transactions

• The company issued convertible notes to related parties, including a member of the Board of Directors, for $500,000 during the quarter.
• As of October 31, 2024, accounts payable include $185,700 in board fees due to officers and directors.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity offerings.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers may be concerned about the company's ability to continue supplying products.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to continue growing and supporting its distribution network.
• The company plans to continue partnering with third parties seeking approvals to market SDC-based products outside the U.S.
• The company plans to develop additional proprietary products and applications.
• The company plans to protect and enhance its intellectual property.

Key Dates

Keywords

antimicrobial, silver dihydrogen citrate, SDC, disinfectant, sanitizer, food safety, convertible notes, financial results, going concern, revenue, net loss, operating expenses